Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Naptumomab estafenatox: a new immunoconjugate.

Robinson MK, Alpaugh RK, Borghaei H.

Expert Opin Biol Ther. 2010 Feb;10(2):273-9. doi: 10.1517/14712590903575620. Review.

PMID:
20053143
2.

Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.

Eisen T, Hedlund G, Forsberg G, Hawkins R.

Curr Oncol Rep. 2014 Feb;16(2):370. doi: 10.1007/s11912-013-0370-0. Review.

3.

Inotuzumab ozogamicin as novel therapy in lymphomas.

Wong BY, Dang NH.

Expert Opin Biol Ther. 2010 Aug;10(8):1251-8. doi: 10.1517/14712598.2010.498418. Review.

PMID:
20528256
5.
6.

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications.

Reff ME, Heard C.

Crit Rev Oncol Hematol. 2001 Oct;40(1):25-35. Review.

PMID:
11578914
7.

The promise of monoclonal antibodies for the therapy of cancer.

Gutheil J.

Crit Rev Oncol Hematol. 2001 Apr;38(1):1-2. No abstract available.

PMID:
11255076
8.

Immunoconjugates against solid tumors: mind the gap.

Ricart AD.

Clin Pharmacol Ther. 2011 Apr;89(4):513-23. doi: 10.1038/clpt.2011.8. Epub 2011 Mar 2. Review.

PMID:
21368753
9.

Antibody-targeted drugs for the therapy of cancer.

Pietersz GA, Krauer K.

J Drug Target. 1994;2(3):183-215. Review.

PMID:
7812691
10.

Cancer stromal targeting (CAST) therapy.

Matsumura Y.

Adv Drug Deliv Rev. 2012 Jun 1;64(8):710-9. doi: 10.1016/j.addr.2011.12.010. Epub 2011 Dec 24. Review.

PMID:
22212902
11.

Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity.

Lech-Maranda E, Robak E, Korycka A, Robak T.

Mini Rev Med Chem. 2007 Oct;7(10):1062-9. Review.

PMID:
17979809
12.

Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.

Bajaj M, Heath EI.

Expert Opin Biol Ther. 2011 Nov;11(11):1519-24. doi: 10.1517/14712598.2011.610788. Epub 2011 Aug 31. Review.

PMID:
21877997
13.

Drug-conjugated monoclonal antibodies for the treatment of cancer.

Lambert JM.

Curr Opin Pharmacol. 2005 Oct;5(5):543-9. Review.

PMID:
16087399
14.

Challenges in the development and manufacturing of antibody-drug conjugates.

Ducry L.

Methods Mol Biol. 2012;899:489-97. doi: 10.1007/978-1-61779-921-1_29.

PMID:
22735971
15.

The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.

Keir CH, Vahdat LT.

Expert Opin Biol Ther. 2012 Feb;12(2):259-63. doi: 10.1517/14712598.2012.642357. Epub 2012 Jan 9. Review.

PMID:
22229970
16.

Technology insight: cytotoxic drug immunoconjugates for cancer therapy.

Ricart AD, Tolcher AW.

Nat Clin Pract Oncol. 2007 Apr;4(4):245-55. Review.

PMID:
17392715
17.

Investigational antibody drug conjugates for solid tumors.

Sapra P, Hooper AT, O'Donnell CJ, Gerber HP.

Expert Opin Investig Drugs. 2011 Aug;20(8):1131-49. doi: 10.1517/13543784.2011.582866. Epub 2011 May 23. Review.

PMID:
21599617
18.

Cationization of monoclonal antibodies: another step towards the "magic bullet"?

Vaisitti T, Deaglio S, Malavasi F.

J Biol Regul Homeost Agents. 2005 Jul-Dec;19(3-4):105-12. Review.

PMID:
16602624
19.

New patented histone deacetylase inhibitors.

Wang H, Dymock BW.

Expert Opin Ther Pat. 2009 Dec;19(12):1727-57. doi: 10.1517/13543770903393789. Review.

PMID:
19939190
20.

Supplemental Content

Support Center